A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Sponsor:
- Immunocore Limited
- Sponsor Study ID:
- IMC-F106C-301
- CTO #:
- 104305
- NCT Number:
- NCT06112314
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Melanoma, Skin
- Study Objectives:
- To compare PFS for brenetafusp + nivolumab to nivolumab regimens.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Jenkins, Russell W, at jenkinr@musc.edu
- Study Coordinator, Newman, Eva, at newmanev@musc.edu
Trial opened at the following institutions:
Medical University of South Carolina